Altimmune, Inc. (NASDAQ:ALT) Shares Purchased by Invesco Ltd.

Invesco Ltd. grew its position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 679.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 247,086 shares of the company's stock after purchasing an additional 215,375 shares during the period. Invesco Ltd. owned approximately 0.35% of Altimmune worth $1,781,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. bought a new stake in Altimmune in the fourth quarter worth $45,000. Cullen Frost Bankers Inc. purchased a new position in Altimmune during the 4th quarter valued at $72,000. 180 Wealth Advisors LLC bought a new position in Altimmune in the 4th quarter valued at $78,000. KLP Kapitalforvaltning AS purchased a new stake in Altimmune in the fourth quarter worth $81,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Altimmune during the fourth quarter valued at $88,000. Institutional investors own 78.05% of the company's stock.

Insider Activity

In other news, CFO Gregory L. Weaver purchased 10,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares of the company's stock, valued at $52,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 4.10% of the company's stock.

Altimmune Stock Performance

NASDAQ:ALT traded down $0.20 during midday trading on Monday, reaching $5.57. 472,970 shares of the stock traded hands, compared to its average volume of 2,848,397. The stock has a market capitalization of $429.28 million, a PE ratio of -3.60 and a beta of 1.13. Altimmune, Inc. has a 12-month low of $3.55 and a 12-month high of $11.16. The business has a 50-day moving average of $5.16 and a two-hundred day moving average of $6.65.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.01. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. Research analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ALT shares. HC Wainwright restated a "buy" rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday, April 3rd. Stifel Nicolaus initiated coverage on Altimmune in a research note on Wednesday, January 8th. They set a "buy" rating and a $18.00 price target on the stock. Finally, William Blair reissued a "market perform" rating on shares of Altimmune in a research report on Friday, March 14th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $20.83.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.